Shots:

• The P-IIa study involves assessing of BL-8040 + Keytruda in 20 patients with metastatic pancreatic cancer who progressed after at least one prior line of chemotherapy
• The overall median time to progression was 2 mos. - while the median time to progression for patients showing disease control was 7 mos. and mOS was 7 mos. - while median survival for the patients showing disease control was 12 mos.- was well-tolerated results plus showed 20% disease control rate
• BL-8040 is a short synthetic peptide acting as an antagonist for a chemokine receptor CXCR4 and is also being evaluated in P-IIa COMBAT/KEYNOTE-202 study in combination with Keytruda and CT for patients with metastatic pancreatic cancer patients. BioLineRx in-licensed BL-8040 from Biokine Therapeutics

Click here to­ read full press release/ article | Ref: BioLineRx | Image: Twitter